Shots:
- ELIAS Animal Health has reported interim data from an ongoing study of ELIAS Cancer Immunotherapy (ECI) + CT in dog with osteosarcoma
- Trial assessed carboplatin (single dose) followed by ECI after 21 days (n=14) vs carboplatin alone (4 doses; n=14), showing 1yr. survival rates of 71% vs 21%; data was presented at ACVIM Forum 2025
- ECI is a USDA-approved adoptive cell therapy which integrates an autologous vaccine with activated T cells to target cancer cells in the treatment of canine osteosarcoma
Ref: Prnewswire | Image: Elais animal health| Press Release
Related News:- Gilead Reports the US FDA’s Approval of Yeztugo (Lenacapavir) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV in Individuals at Risk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
